Anhui Anke BioTech Group Total Liabilities
Anhui Anke BioTech Group total liabilities. Based on the latest financial reports, Anhui Anke BioTech Group (300009) has total liabilities worth CN¥714.45 Million CNY (≈ $104.55 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Anhui Anke BioTech Group asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Anhui Anke BioTech Group (2006–2025)
Total liabilities of Anhui Anke BioTech Group from 2006 to 2025. This chart illustrates how Anhui Anke BioTech Group's total liabilities have evolved over time, based on quarterly financial data. Explore Anhui Anke BioTech Group (300009) long-term investment share to see how much of total assets are deployed in long-term investments.
Anhui Anke BioTech Group Competitors by Total Liabilities
The table below lists competitors of Anhui Anke BioTech Group ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shilpa Medicare Limited
NSE:SHILPAMED
|
India | Rs10.57 Billion |
|
Dermapharm Holding SE
XETRA:DMP
|
Germany | €1.54 Billion |
|
Grupo Profuturo S.A.B. de C.V
MX:GPROFUT
|
Mexico | MX$152.08 Billion |
|
Diebold Nixdorf, Incorporated
NYSE:DBD
|
USA | $2.76 Billion |
|
Transportadora de Gas del Sur SA B
BA:TGSU2
|
Argentina | AR$2.70 Trillion |
|
Bumitama Agri Ltd
F:2BU
|
Germany | €5.50 Trillion |
|
Zhejiang Fulai New Material Co.Ltd.
SHG:605488
|
China | CN¥1.98 Billion |
Liability Composition Analysis (2006–2025)
This chart breaks down Anhui Anke BioTech Group's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Anhui Anke BioTech Group.
Liquidity & Leverage Metrics
Anhui Anke BioTech Group Total Liabilities Ratios Explained
Anhui Anke BioTech Group total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Anhui Anke BioTech Group's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Anhui Anke BioTech Group (2006–2025)
The table below shows the annual total liabilities of Anhui Anke BioTech Group from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥811.30 Million ≈ $118.72 Million |
-2.89% |
| 2024-12-31 | CN¥835.41 Million ≈ $122.25 Million |
-17.97% |
| 2023-12-31 | CN¥1.02 Billion ≈ $149.03 Million |
+19.09% |
| 2022-12-31 | CN¥855.17 Million ≈ $125.14 Million |
+11.71% |
| 2021-12-31 | CN¥765.52 Million ≈ $112.02 Million |
+27.53% |
| 2020-12-31 | CN¥600.29 Million ≈ $87.84 Million |
+14.08% |
| 2019-12-31 | CN¥526.19 Million ≈ $77.00 Million |
+2.00% |
| 2018-12-31 | CN¥515.86 Million ≈ $75.49 Million |
+4.48% |
| 2017-12-31 | CN¥493.73 Million ≈ $72.25 Million |
-8.41% |
| 2016-12-31 | CN¥539.04 Million ≈ $78.88 Million |
+326.18% |
| 2015-12-31 | CN¥126.48 Million ≈ $18.51 Million |
-10.99% |
| 2014-12-31 | CN¥142.11 Million ≈ $20.79 Million |
+59.29% |
| 2013-12-31 | CN¥89.21 Million ≈ $13.05 Million |
+22.37% |
| 2012-12-31 | CN¥72.91 Million ≈ $10.67 Million |
+21.98% |
| 2011-12-31 | CN¥59.77 Million ≈ $8.75 Million |
-11.12% |
| 2010-12-31 | CN¥67.25 Million ≈ $9.84 Million |
+43.24% |
| 2009-12-31 | CN¥46.95 Million ≈ $6.87 Million |
-36.83% |
| 2008-12-31 | CN¥74.32 Million ≈ $10.88 Million |
-25.28% |
| 2007-12-31 | CN¥99.46 Million ≈ $14.55 Million |
-4.11% |
| 2006-12-31 | CN¥103.72 Million ≈ $15.18 Million |
-- |
About Anhui Anke BioTech Group
Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. It offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name… Read more